Bicara Therapeutics Inc. (BCAX)

Compare

11.83

-1.43

(-10.78%)

At close: April 3 at 4:00:01 PM EDT

11.64

-0.19

(-1.61%)

Pre-Market: 8:00:01 AM EDT

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Dosing commenced in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Strong financial position with approximately $490 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transforma

GlobeNewswire 8 days ago

BCAX
-10.78%
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that three abstracts relating to the company’s lead product candidate, ficerafusp alfa, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will be held from April 25-30, 2025 in Chicago, IL. Ficerafusp alfa is a first

GlobeNewswire 9 days ago

BCAX
-10.78%
Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 23 days ago

BCAX
-10.78%
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 3:10 p.m. ET. A live webcast of the presentation will be available at Events and Presentations. A replay of the webcas

GlobeNewswire last month

BCAX
-10.78%
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the first patients have been enrolled in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ficerafusp alfa is a first-in-class bifu

GlobeNewswire last month

BCAX
-10.78%
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

BOSTON, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the presentation of data from the Phase 1/1b dose expansion cohort of ficerafusp alfa in combination with pembrolizumab in patients with second line (2L) or later squamous cancer of the anal canal (SCAC). The results were presented in a poster session during the 2025

GlobeNewswire 2 months ago

BCAX
-10.78%
Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia

The GLP-RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

Clinical Trials Arena 2 months ago

BCAX
-10.78%
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full exercise of the underwriters’ option to purchase additional shares Strong financial position with approximately $521 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a cl

GlobeNewswire 4 months ago

BCAX
-10.78%
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics, will present at the Stifel 2024 Healthcare Conference in New York, NY on Tuesday, November 19, 2024 at 9:10 a.m. ET. A live webcast of the presentation will be available on the Events an

GlobeNewswire 4 months ago

BCAX
-10.78%
Opening Day: Another trio of biotech IPOs make Friday debut

The Partners Group-backed KinderCare sold 24 million shares for $24 each this Tuesday. At the IPO price, the childhood education company had a market value of $2.74B, based on the outstanding shares. Sky Quarry, Click Holdings, and SKK Holdings also opened for trading this week. Meanwhile, a new trio of biotech companies’ shares came to market on Friday as Upstream Bio, Ceribell and Camp4 Therapeutics each made their public debut. In mid-September, Bicara Therapeutics (BCAX), MBX Biosciences (MB

TipRanks 5 months ago

C

CBLL
-2.65%
ZBIO
-7.47%
MBX Biosciences earns Buy rating at three investment firms

Investing.com -- Three major investment firms started research coverage of MBX Biosciences stock on Tuesday, each assigning a Buy rating to the biotechnology company.

Investing.com 5 months ago

BCAX
-10.78%
RA Capital Management's Strategic Acquisition of Bicara Therapeutics Shares

On September 16, 2024, RA Capital Management, L.P., a prominent investment firm, executed a significant transaction by acquiring 6,955,993 shares of Bicara Therapeutics Inc (NASDAQ:BCAX). This move not only reflects RA Capital's strategic investment approach but also highlights its focus on innovative biotechnology ventures. Located at 200 Berkeley Street, 18th Floor, Boston, MA, RA Capital Management is a well-established investment firm specializing in the healthcare and financial services sectors.

GuruFocus.com 6 months ago

BCAX
-10.78%
FMR LLC Acquires New Stake in Bicara Therapeutics Inc

On September 16, 2024, FMR LLC (Trades, Portfolio) marked a significant portfolio addition by purchasing 2,495,333 shares of Bicara Therapeutics Inc (NASDAQ:BCAX), a clinical-stage biopharmaceutical company. This transaction, executed at a price of $25.41 per share, represents a new holding for the firm within its diverse investment portfolio. FMR LLC (Trades, Portfolio), commonly known as Fidelity, was established in 1946 and has since been at the forefront of investment management.

GuruFocus.com 6 months ago

BCAX
-10.78%
Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity

Bicara was one of three biotechs that went public last week in one of the busiest biotech IPO windows this year.

Pharmaceutical Technology 6 months ago

BCAX
-10.78%
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced the closing of its initial public offering of 20,125,000 shares of its common stock at a public offering price of $18.00 per share, which includes 2,625,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of

GlobeNewswire 6 months ago

BCAX
-10.78%
TPG-backed Bicara Therapeutics raises $315 million in US IPO

Bicara is among several drug developers that will test investor appetite with their IPOs in the coming weeks. The company had initially planned on selling about 11.8 million shares, but Bicara upsized the offering to 14.7 million shares on Wednesday. Bicara's lead drug, ficerafusp alfa, is currently in an early-stage study in the U.S. to treat a type of head and neck cancer in combination with Merck's Keytruda.

Reuters 6 months ago

BCAX
-10.78%
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the pricing of its initial public offering of 17,500,000 shares of its common stock at a public offering price of $18.00 per share. Bicara Therapeutics’ shares are expected to begin trading on the Nasdaq Global Market on September 13, 2024 under the ticker symbol “B

GlobeNewswire 6 months ago

BCAX
-10.78%
Three biotechs raise $700M in rare burst of IPO activity

Bicara Therapeutics, Zenas BioPharma and MBX Biosciences each priced upsized IPOs in the busiest week for biotech stock sales since February.

BioPharma Dive 6 months ago

BCAX
-10.78%

Performance Overview

Return	BCAX	S&P 500 (^GSPC)
YTD	-32.09%	-8.25%
1-Year	-54.93%	+3.55%
3-Year	-54.93%	+18.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025

Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

Opening Day: Another trio of biotech IPOs make Friday debut

MBX Biosciences earns Buy rating at three investment firms

RA Capital Management's Strategic Acquisition of Bicara Therapeutics Shares

FMR LLC Acquires New Stake in Bicara Therapeutics Inc

Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

TPG-backed Bicara Therapeutics raises $315 million in US IPO

Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering

Three biotechs raise $700M in rare burst of IPO activity

Performance Overview